MYO

$0.72

Post-MarketAs of Mar 17, 8:00 PM UTC

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$0.72
Potential Upside
5%
Whystock Fair Value$0.76
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled up...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$27.77M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.13
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-86.24%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
2.69

Recent News

Simply Wall St.
Mar 12, 2026

Elevance Expands Myomo Coverage To Support Tech Enabled Care Narrative

Elevance Health (NYSE:ELV) entered into new network participation agreements with Myomo. The agreements expand coverage for advanced orthotic devices to tens of millions of Elevance members. Coverage spans commercial, Medicare Advantage, and Medicaid plans, adding to Elevance's technology-enabled care offerings. For you as an investor, this move speaks directly to how Elevance Health is shaping its core health benefits business around technology-enabled, patient-centered care. The Myomo...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Mar 12, 2026

Myomo Inc (MYO) Q4 2025 Earnings Call Highlights: Record Revenue Amid Rising Expenses and ...

Despite achieving its highest revenue quarter, Myomo Inc (MYO) faces increased operating losses and outlines strategic initiatives for future growth.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 9, 2026

Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates

Myomo (MYO) delivered earnings and revenue surprises of +5.88% and +11.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 6, 2026

Cresco Labs Inc. (CRLBF) Reports Q4 Loss, Beats Revenue Estimates

Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of +14.16% and +0.26%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.
GuruFocus.com
Nov 11, 2025

Myomo Inc (MYO) Q3 2025 Earnings Call Highlights: Strong International Growth Amidst Domestic ...

Myomo Inc (MYO) reports robust revenue growth in Germany, but faces domestic hurdles with decreased margins and increased operating expenses.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.